Recursion Pharmaceuticals RXRX is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $28.73 billion ...

Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In recent days, Recursion Pharmaceuticals announced a major leadership transition appointing Najat Khan, Ph.D., as CEO effective January 1, 2026, while also securing a milestone payment from Roche and ...

In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine learning to create new drugs. Recursion ...

Recursion's share price continues to be volatile, despite its pipeline maturing and the injection of significant cash through its merger with Exscientia. While early clinical data has been marginal, ...

Q3 2025 Management View Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier this ...